SHIFTBIO is excited to announce that one of SBI's leading programs has been accepted for publication in Nature Communications.
This astounding work highlights:
- In vivo macrophage reprogramming through dual-mode of action
- Scalable manufacturing process demonstrated by a large-scale process that ensures high yield and purity
Notably, this program has previously received a U.S. FDA Orphan Drug Designation.
These milestones underscore the scientific rigor and highlight the transformative potential of SBI's assets as we continue to push the boundaries of innovative drug development. They also tell a powerful story: robust science meets clinical promise, paving the way for SBI to make a meaningful impact in medicine.
We extend our sincere appreciation to our dedicated team and esteemed collaborators. Please stay tuned for more exciting milestones.
Learn more here:
https://www.nature.com/articles/s41467-025-57133-w
SHIFTBIO is excited to announce that one of SBI's leading programs has been accepted for publication in Nature Communications.
This astounding work highlights:
- In vivo macrophage reprogramming through dual-mode of action
- Scalable manufacturing process demonstrated by a large-scale process that ensures high yield and purity
Notably, this program has previously received a U.S. FDA Orphan Drug Designation.
These milestones underscore the scientific rigor and highlight the transformative potential of SBI's assets as we continue to push the boundaries of innovative drug development. They also tell a powerful story: robust science meets clinical promise, paving the way for SBI to make a meaningful impact in medicine.
We extend our sincere appreciation to our dedicated team and esteemed collaborators. Please stay tuned for more exciting milestones.
Learn more here:
https://www.nature.com/articles/s41467-025-57133-w